Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

174.83USD
22 Nov 2017
Change (% chg)

$4.16 (+2.44%)
Prev Close
$170.67
Open
$171.00
Day's High
$176.08
Day's Low
$170.15
Volume
2,856,367
Avg. Vol
3,124,582
52-wk High
$256.80
52-wk Low
$169.61

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $58,145.50
Shares Outstanding(Mil.): 332.58
Dividend: 0.70
Yield (%): 1.60

Financials

  Industry Sector
P/E (TTM): -- 31.69 15.46
EPS (TTM): -- -- --
ROI: -- 15.18 11.85
ROE: -- 16.59 15.83

Teva Pharmaceutical set for major layoffs in Israel, U.S. -report

TEL AVIV, Nov 23 Teva Pharmaceutical Industries is expected to cut 20-25 percent of its 6,860 workers in Israel and a few thousand more in the United States, financial news website Calcalist reported on Thursday.

4:04am EST

Allergan may pursue lawsuit against drug compounder Imprimis

Allergan PLC can proceed with a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan's dry eye drug, Restasis, a federal judge has ruled.

Nov 16 2017

BRIEF-‍GIC Private reports a 5.11 pct passive stake in Allergan ​

* As of Nov 8, ‍GIC Private reports a 5.11 pct passive stake in - SEC filing ​ Source text: (http://bit.ly/2zMOtvp) Further company coverage:

Nov 16 2017

BRIEF-Paulson & Co dissolves share stake in Facebook, cuts share stake in Allergan

* Paulson & Co Inc dissolves share stake in Facebook Inc ‍​- SEC filing

Nov 14 2017

BRIEF-Omega Advisors takes share stake in Aetna, dissolves stake in Allergan

* Cuts share stake in AIG to 841,740 shares from 1.3 million shares

Nov 14 2017

Allergan to sell a quarter of its Teva stake in first quarter of 2018

NEW YORK Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

Nov 13 2017

Allergan to sell a quarter of its Teva stake in Q1 2018

NEW YORK, Nov 13 Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

Nov 13 2017

BRIEF-Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia

* Allergan receives FDA approval for use of Vraylar (cariprazine) in the maintenance treatment of schizophrenia

Nov 13 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Nov 10 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH, Nov 10 Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Nov 10 2017

Earnings vs. Estimates